{
    "url_original": "https://www.wsj.com/articles/biogen-agrees-to-sell-biosimilar-venture-stake-to-partner-samsung-biologics-11643333259?mod=business_lead_pos2",
    "url": "biogen-agrees-to-sell-biosimilar-venture-stake-to-partner-samsung-biologics-11643333259",
    "title": "Biogen to Sell Biosimilar-Venture Stake to Partner Samsung Biologics",
    "sub_head": "Deal for its 50% ownership of the joint venture would bring the company at least $2.25 billion",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-475804?width=860&height=573",
    "image_1": "im-475804.jpg",
    "time": "2022-01-27 20:27:00",
    "body": "Biogen Inc. is selling its share in biosimilar joint venture  Samsung  Bioepis for at least $2.25 billion to partner  Samsung Biologics ,  adding to its cash pile after the disappointing launch of its Alzheimerâ€™s disease drug Aduhelm.<br />Biogen and Samsung Biologics created Samsung Bioepis in 2012 to develop, manufacture and market biosimilar drugs, lower-priced copies of drugs made from living cells, including the rheumatoid-arthritis treatments Enbrel and Humira."
}